Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;84(6):1523-1537.
doi: 10.1016/j.jaad.2021.02.073. Epub 2021 Mar 5.

Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy

Carmen M Montagnon  1 , Julia S Lehman  2 , Dedee F Murrell  3 , Michael J Camilleri  2 , Stanislav N Tolkachjov  4
Affiliations
Review

Intraepithelial autoimmune bullous dermatoses disease activity assessment and therapy

Carmen M Montagnon et al. J Am Acad Dermatol. 2021 Jun.

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Am Acad Dermatol. 2021 Sep;85(3):799. doi: 10.1016/j.jaad.2021.06.005. Epub 2021 Jun 5. J Am Acad Dermatol. 2021. PMID: 34119353 No abstract available.

Abstract

Intraepithelial autoimmune blistering dermatoses are a rare group of skin disorders characterized by disruptions of inter-keratinocyte connections within the epidermis through the action of autoantibodies. The second article in this continuing medical education series presents validated disease activity scoring systems, serologic parameters of disease, treatments, and clinical trials for pemphigus and its subtypes.

Keywords: IVIG; Pemphigus Disease Activity Index; azathioprine; dapsone; intraepithelial autoimmune bullous dermatoses; mycophenolate mofetil; paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome; pemphigus erythematosus; pemphigus foliaceus; pemphigus herpetiformis; pemphigus vulgaris; rituximab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest None disclosed.

MeSH terms